Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Transduction01:16

Transduction

42
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome...
42
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026
Same author

Editor's Note: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Cancer research·2026
Same author

Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.

Pigment cell & melanoma research·2026
Same author

Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy-Treated Melanoma.

Cancer immunology research·2025
Same author

Aqueous humor biomarkers in ocular oncology: Insights and advances.

Cell reports. Medicine·2025
Same author

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models.

Nature communications·2025

Related Experiment Video

Updated: Jul 20, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Targeting TEAD-ious resistance.

Connor A Ott1, Andrew E Aplin2

  • 1Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Trends in Cancer
|August 5, 2023
PubMed
Summary
This summary is machine-generated.

Resistance to KRAS inhibitors can be overcome by targeting the TEAD transcription factor. A novel TEAD inhibitor, GNE-7883, may enhance the durability of KRAS inhibitors in cancer patients.

Keywords:
G12CKRASTAZTEADTEAD inhibitorYAPdrug toleranceresistance

More Related Videos

Protocols for Robust Herbicide Resistance Testing in Different Weed Species
10:52

Protocols for Robust Herbicide Resistance Testing in Different Weed Species

Published on: July 2, 2015

14.7K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.2K

Related Experiment Videos

Last Updated: Jul 20, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Protocols for Robust Herbicide Resistance Testing in Different Weed Species
10:52

Protocols for Robust Herbicide Resistance Testing in Different Weed Species

Published on: July 2, 2015

14.7K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Targeting KRAS mutations is a key strategy in cancer therapy.
  • Resistance to KRAS inhibitors remains a significant clinical challenge.
  • The KRAS signaling pathway is crucial for cancer cell proliferation and survival.

Purpose of the Study:

  • To investigate the potential of targeting the TEAD transcription factor to overcome resistance to KRAS inhibitors.
  • To evaluate the efficacy of a novel TEAD inhibitor, GNE-7883, in preclinical cancer models.
  • To explore the role of TEAD in mediating resistance to KRAS-targeted therapies.

Main Methods:

  • Utilized a novel inhibitor, GNE-7883, targeting the TEAD transcription factor.
  • Conducted studies in relevant cancer models exhibiting KRAS mutations and resistance.
  • Assessed the impact of GNE-7883 on KRAS signaling pathways and tumor growth.

Main Results:

  • GNE-7883 demonstrated efficacy in overcoming resistance to existing KRAS inhibitors.
  • Inhibition of TEAD signaling by GNE-7883 showed anti-tumor activity.
  • The study provides evidence for the therapeutic potential of combining KRAS and TEAD inhibitors.

Conclusions:

  • TEAD inhibitors, such as GNE-7883, represent a promising strategy to enhance the durability of KRAS inhibitors.
  • Targeting the TEAD transcription factor may overcome acquired resistance to KRAS-targeted therapies in cancer.
  • Further clinical investigation of TEAD inhibitors is warranted for patients with KRAS-mutated cancers.